

## Editorial

# Heterogeneity Perspectives of Sarcomas

Jassem G Mahdi<sup>1\*</sup> and Eamon J Mahdi<sup>2</sup>

<sup>1</sup>Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

<sup>2</sup>Cardiff School of Medicine, Cochrane Medical Education Centre, Heath Park, Cardiff, UK

\*Corresponding author: Jassem G Mahdi, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

Received: February 06, 2016; Accepted: February 08, 2016; Published: February 10, 2016

## Editorial

Connective tissue is widely distributed in the human body to help support the musculoskeletal system and organs. These tissues include blood vessels, bones, cartilage, fat, muscles, nerves, and tendons. Such tissues are subject to malignant tumours when they are exposed to intrinsic or extrinsic carcinogenic factors, termed sarcoma, or fleshy substance [1]. This heterogeneous category of cancer includes more than 100 subgroups involves two main types, osteosarcoma, related to bone and soft tissues which both comprises of approximately 1% of all cancer diagnoses [2]. All types of sarcoma occur in different ages, including infants to adults. Although there are outliers within each type of sarcoma, the most common sarcomas across all ages are rhabdomyosarcoma, Ewing, synovial and liposarcoma [3] (Table 1).

Most of these sarcomas originate from mesenchymal stem cells [4-5]. The mesenchymal neoplasm cells are characterised by different staging, signalling pathways and type of tissue, reflecting the complexity of diagnoses and treatments [6-7]. Researchers have indicated that sarcomas are not an individual disease unlike carcinomas, which may be investigated in a less complex manner [7-10]. The heterogeneity of sarcomas requires a more strategic approach to fully understand tumour biological and physiology perspectives of each individual type of malignant connective tissues [11]. The use of specific animal models is important to demonstrate the actual mechanism of how a cell is developed into an individual sarcoma. The advantage of animal models is that they provide a natural environment to show how the cell proceeds into sarcoma, compared to in vitro approach. It also helps to investigate proteomics for understanding gene expression and cellular functions of proteins, as well as the process of the initiation, promotion and progression of the development of sarcoma. Thus, the major challenges in diagnosis and treatment of sarcomas require interdisciplinary efforts to help identify the diagnostic proteomics profile for various sarcomas. These can contribute to the potential clinical testing, especially at the early stages of sarcomas. Per se much effort is needed to distinguish various abnormal proteins in different connective tissues disorders. Since different sarcomas may overlap in their clinical perspectives, more advanced research should be considered as a major importance which is vital for therapeutic approaches.

Proteins are essential macromolecules that carry different functions within connective tissues and the rest of the body. Human

proteins are directly associated with the 20,000-25,000 protein-coding genes [12]. Therefore, the structure of the individual protein is not only associated with primary structure but also with its folding, which determines the secondary, tertiary and quaternary structures. The combinations of these structures are associated with the folding of protein molecules to achieve their proper conformation and function within its complex microenvironment [13]. However, protein misfolding gives rise to abnormal protein, with an abnormal conformation which often leads to revoke its specific physiological vital function. The permanent dysfunction of proteins often results in defecting homeostatic mechanisms, or encourages pathological conditions in normal connective tissues [14-17]. The large efforts of researchers have given significant insights into the molecular features of sarcomas in relation to diagnosis and treatment [18]. It is important to consider both oncogenic mutations and complex genomic rearrangements. These changes often contribute significantly in causing abnormalities of the conformation of the expressed proteins, resulting in a wide range of clinical, histological and molecular characteristics [17, 19-21].

The main molecular pathogenesis that underlines the development of sarcoma is associated with a specific chromosomal translocation, resulting in a fusion gene and subsequently producing fused proteins. Sarcomas can be resulted from different types of fusion (Table 2) to disrupt cell biology via chimeric transcriptional regulation, over expression, or altering signalling by changing cellular localization or activity of a signalling protein [22-23]. To understand the genetic manipulation that leads to sarcomas, it is important to understand the significance of conformational structures of macromolecule, mainly the DNA and the process of the transcription of certain protein. Connective tissues in their complex microenvironments can influence the nature of the chemical structure and function of the macromolecules. Both intrinsic and extrinsic factors may play important roles in chromosomal translocation affecting a certain locus on the DNA but this depends on the susceptibility of the DNA sequence to break, in which cellular stress and transcriptional activity trans activities play a major part in the genomic rearrangements [24]. Various studies have considered that genomic rearrangements are not random but fall into four categories: proximity of chromosomal regions in the nucleus, cellular stress, inappropriate DNA repair or recombination, and DNA sequence and chromatin features [25-26].

Although researchers have identified the genetic abnormality of sarcomas, targeted therapy remains a critical issue. The diversity of these heterogeneous diseases poses challenges related to diagnosis,

**Table 1:** Most common sarcomas.

| Sarcoma          | Age (Year) | Subtype   |
|------------------|------------|---|
| Rhabdomyosarcoma | < 7        | tumour of striated muscle                           |
| Ewing            | 10-20      | Bone cancer, frequently long bones of legs and arms |
| Synovial         | 30-40      | Osteoarthritis                                      |
| Liposarcoma      | 50-70      | malignancy of fat cells                             |

**Table 2:** Some examples to chromosomal translocation.

| Sarcoma                   | Translocation     | Gene             |
|---------------------------|-------------------|------------------|
| Alveolar rhabdomyosarcoma | t(2;13)(q35;q14)  | PAX3-FKHR [27]   |
|                           | t(1;13)(p36;q14)  | PAX7-FKHR [28]   |
| Ewing                     | t(11;22)(q24;q12) | EWS-FLI1 [29]    |
|                           | t(21;22)(q22;q12) | EWS-ERG [29-30]  |
|                           | t(7;22)(p22;q12)  | EWS-ETV1 [30]    |
|                           | t(17;22)(q12;q12) | EWS-FEV [30]     |
|                           | t(2;22)(q33;q12)  | EWS-E1AF [30]    |
| Synovial                  | t(16;21)(p11;q22) | FUS-ERG [31]     |
|                           | t(X;18)(p11;q11)  | SSX1-SYT [32-33] |
|                           |                   | SSX2-SYT [32-33] |
| Synovial Liposarcoma      | t(12;16)(q13;p11) | TLS-CHOP [34]    |
|                           | t(12;22)(q13;q12) | EWS-CHOP [34]    |

aggressiveness, and drug resistance [35-38].

Morphology and analyses of gene expression are significant approaches in identifying connective tissue of neoplastic cells. In addition, the grade, size and location of sarcoma, together with the histology can help to prognosticate [39]. In the light of this complexity, an understanding of the pathophysiology of these heterogeneous sarcomas requires multi-discipline researches for developing of additional therapeutic approach, in association with study of the structure and function of mainly chromosomes. The current diagnosis strategy uses the conventional immunohistochemistry and morphology. Although, immunohistochemistry-based diagnosis is often used in sarcomas, it has limitations related to the multi-specificity of most markers and antigenic complexity of many tumour types. Therefore, precise histological analysis is important in studying sarcomas [40-41].

## Conclusion

Animal models and interdisciplinary approaches in specifying certain sarcoma may lead to more effective diagnosis and treatments.

## References

1. Etymology Dictionary. Sarcoma 2015.
2. Cancer Research, UK, 2015. Types of cancer.
3. Wolden SL, Alektiar KM. Sarcomas across the age spectrum. *Semin Radiat Oncol.* 2010; 20: 45-51.
4. Lin PP, Wang Y, Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. *Sarcoma.* 2011.
5. Xiao W, Mohseny AB, Hogendoorn PC, Cleton-Jansen AM. Mesenchymal stem cell transformation and sarcoma genesis. *Clin Sarcoma Res.* 2013; 3: 10.
6. Thomas DM, O'Sullivan B, Gronchi A. Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. *Expert Rev Anticancer Ther.* 2009; 9: 1145-1157.
7. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. *CA Cancer J Clin.* 2006; 56: 282-291.
8. van Driel M, van Leeuwen JP. Cancer and bone: a complex complex. *Arch Biochem Biophys.* 2014; 561: 159-166.
9. Nassif MO, Trabulsi NH, Bullard Dunn KM, Nahal A, Meguerditchian AN. Soft tissue tumors of the anorectum: rare, complex and misunderstood. *J Gastrointest Oncol.* 2013; 4: 82-94.
10. Mullinax JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. *Cancer Control.* 2011; 18: 177-187.
11. Fletcher CD. Soft tissue tumours: Epidemiology, clinical features,

histopathological typing and grading. *Pathology and Genetics of Tumours of Soft Tissue and Bone.* Lyon. 2002.

12. International Human Genome Sequencing Consortium. 2004.
13. Valastyan JS, Lindquist S. Mechanisms of protein-folding diseases at a glance. *Dis Model Mech.* 2014; 7: 9-14.
14. Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. *PLoS One.* 2012; 7: e35050.
15. Coady TH, Manley JL. ALS mutations in TLS/FUS disrupt target gene expression. *Genes Dev.* 2015; 29: 1696-1706.
16. Griffin GK, Sholl LM, Lindeman NI, Fletcher CD, Hornick JL. Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF- $\kappa$ B regulatory genes. *Modern Pathology.* 2015.
17. Kovac M, Blattmann C, Ribl S, Smida J, Mueller NS, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. *Nature communications.* 2015; 6.
18. Fisher C. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. *Virchows Arch.* 2010; 456: 153-166.
19. Halevy O, Rodel J, Peled A, Oren M. Frequent p53 mutations in chemically induced murine fibrosarcoma. *Oncogene.* 1991; 6: 1593-1600.
20. Todorova R. Structure-function based molecular relationships in Ewing's sarcoma. *Biomed Res Int.* 2015: 798426.
21. Zöllner SK, Rössig C, Toretzky JA. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer. *Cancer Metastasis Rev.* 2015; 34: 417-428.
22. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Oncogenic mutations affecting cell proliferation.
23. Cooper GM. *The Cell: A Molecular Approach.* 2nd edition. Sunderland (MA): Sinauer Associates.; Pathways of Intracellular Signal Transduction. 2000.
24. Deel MD, Li JJ, Crose LE, Linardic CM. A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. *Front Oncol.* 2015; 5: 190.
25. Soutoglou E, Misteli T. On the contribution of spatial genome organization to cancerous chromosome translocations. *Journal of the National Cancer Institute. Monographs.* 2007; 16-19.
26. Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. *Nat Rev Genet.* 2010; 11: 819-829.
27. Biegel JA, Nycum LM, Valentine V, Barr FG, Shapiro DN. Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. *Genes Chromosomes Cancer.* 1995; 12: 186-192.
28. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res.* 1994; 54: 2869-2872.
29. Sorensen PH, Liu XF, Delattre O, Rowland JM, Biggs CA, Thomas G, et al. Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. *Diagnostic Molecular Pathology.* 1993; 2: 147-157.
30. Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. *J Clin Oncol.* 1999; 17: 1809-1814.
31. Im YH, Kim HT, Lee C, Poulin D, Welford S, Sorensen PH. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. *Cancer Res.* 2000; 60: 1536-1540.
32. Storlazzi CT, Mertens F, Nascimento A, Isaksson M, Wejde J, Brosjo O. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. *Hum Mol Genet.* 2003; 12: 2349-2358.

33. dos Santos NR, de Bruijn DR, Balemans M, Janssen B, Gärtner F, Lopes JM. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. *Hum Mol Genet.* 1997; 6: 1549-1558.
34. Panagopoulos I, Mertens F, Isaksson M, Limon J, Gustafson P, Skytting B. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. *Genes Chromosomes Cancer.* 2001; 31: 362-372.
35. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. *Int J Oncol.* 2009; 34: 1381-1386.
36. Martín Liberal J, Lagares-Tena L, Sáinz-Jaspeado M, Mateo-Lozano S, García del Muro X, Tirado OM. Targeted therapies in sarcomas: challenging the challenge. *Sarcoma.* 2012.
37. Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. *Oncotarget.* 2015.
38. Shen R, Zhang J, Zhang F, Du Y, Liang W, Xu L, et al. Clinical characteristics and therapeutic analysis of 51 patients with Marjolin's ulcers. *Experimental and therapeutic medicine.* 2015; 10: 1364-1374.
39. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. *J Clin Oncol.* 1996; 14: 1679-1689.
40. Miettinen M. Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers. *Histopathology.* 2014; 64: 101-118.
41. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. *Ann Surg.* 2003; 238: 358-370.